Unknown

Dataset Information

0

Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576


ABSTRACT: Ibrutinib-based therapies are costly and require continuous administration. We hypothesized combining BTK inhibition with anti-CD20 monoclonal antibodies would yield deep remissions allowing discontinuation. We enrolled 32 therapy-naïve CLL patients to receive ibrutinib plus obinutuzumab, followed by single-agent ibrutinib. Patients could discontinue ibrutinib after 36 months with sustained complete response (CR). We evaluated treatment safety, efficacy, and outcomes after ibrutinib discontinuation. The overall response rate was 100%, 28% achieved a CR, and 12.5% achieved bone marrow undetectable minimal residual disease. At a three-year median follow-up, 91% remain in remission with 100% overall survival. Five patients in sustained CR stopped ibrutinib and have not progressed. Eight non-CR patients discontinued for other reasons, with only two progressing. The treatment was safe, with a lower IRR rate. All patients responded to treatment with longer time-to-progression after discontinuation of ibrutinib. Our data support the evaluation of ibrutinib discontinuation strategies in more extensive clinical trials (https://Clinicaltrials.gov Identifier https://clinicaltrials.gov/ct2/show/NCT02315768).

SUBMITTER: Castro J 

PROVIDER: S-EPMC8800600 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC6182267 | biostudies-literature
| S-EPMC5384733 | biostudies-other
| S-EPMC4905707 | biostudies-other
| S-EPMC9326222 | biostudies-literature
| S-EPMC4520535 | biostudies-literature
| S-EPMC6706803 | biostudies-literature
| S-EPMC6593416 | biostudies-literature
| S-EPMC5909068 | biostudies-literature
| S-EPMC7605394 | biostudies-literature
| S-EPMC5590803 | biostudies-literature